http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고립성 폐결절로 발현한 파종성 림프절 외 변연부 B-세포 림프종
조준현 ( Joon Hyun Cho ),정종필 ( Jong Pil Jung ),차희정 ( Hee Jeong Cha ),박창률 ( Chang Ryul Park ),김성률 ( Sung Ryul Kim ),김혁 ( Hawk Kim ),박진우 ( Jin Woo Park ),우순주 ( Soon Joo Woo ),엄은아 ( Eun A Eum ),이기영 ( Ki You 대한결핵 및 호흡기학회 2006 Tuberculosis and Respiratory Diseases Vol.61 No.2
Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is usually indolent. Although it was reported recently that about 20-30% cases of MALT lymphoma presented with a disseminated disease at diagnosis, it was described as a disease localized at diagnosis and remaining stable for a prolonged period. However, only a few cases of MALT lymphoma involved the lung and gastrointestinal tract all at once. We report a case of a 73-year-old man with disseminated MALT lymphoma. He presented with non-productive cough, initial chest radiograph showed a nodule in the right lower lobe. The diagnosis of stage IV MALT lymphoma was made by CT scan, video-assisted thoracoscopic excisional biopy, gastrofiberscopic biopsy and bone marrow biopsy. The lymphoma involved the lung, stomach and bone marrow at the time of diagnosis. Because he refused chemotherapy, he discharged after Helicobacter pylori eradication without chemotherapy. Regular follow-up examination did not show any evidence of disease progression over 22 months. (Tuberc Respir Dis 2006; 61: 171-177)
Alemtuzumab을 이용한 이차성 순적혈구 빈혈의 치료
박혜민 ( Hye Min Park ),임재욱 ( Jae Uk Im ),박주환 ( Ju Hwan Park ),김은혜 ( En Hye Kim ),전홍길 ( Hong Gil Jun ),박재후 ( Jae Hoo Park ),김혁 ( Hawk Kim ) 대한내과학회 2013 대한내과학회지 Vol.85 No.2
Pure red cell aplasia (PRCA) in adults is usually idiopathic, although some underlying conditions can cause PRCA. Immunosuppressive therapy (IST) is used to treat PRCA, but IST has side effects and may fail. The anti-CD52 monoclonal antibody alemtuzumab (ALM) was recently used to successfully treat therapy-resistant PRCA. We herein report successful treatment of secondary PRCA after erythropoietin therapy using ALM and cyclosporin A (CsA) in one patient. The total dose of ALM was 60 mg over 3 days (10, 20, and 30 mg, respectively) plus CsA for at least 6 months. The patient achieved a complete response 18 months after ALM-CsA treatment and his treatment could be changed to a different erythropoietin stimulating agent. (Korean J Med 2013;85:214-217)